Clinical Trial Update: DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating DFMO as maintenance therapy for molecular high/very high risk and relapsed medulloblastoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medulloblastoma

Drugs mentioned

• DFMO (difluoromethylornithine)

Snippet

Sponsor: Giselle Sholler | Conditions: Medulloblastoma | Phase 2 | Status: RECRUITING